Additionally, oral anti-diabetic agents such as sulphonylurea (48%), meglitinide (28.7%), biguanides (52%), thiazolinidinedione (28.3%), dipeptidyl peptidase 4 (DPP4) inhibitors (49.7%), alpha glucose inhibitors (40%), and sodium-glucose co-transporter (SGLT-2) inhibitors (28.3%) collectively contribute to the multifaceted approach to diabetes treatment. This evidence concerns the gene SLC5A2 and diabetes mellitus.